Protalix BioTherapeutics, Inc.
) announced encouraging initial results from a phase I study on
its pipeline candidate, PRX-112 an oral glucocerebrosidase (GCD)
being evaluated for treating patients suffering from Gaucher
We note that Protalix has one approved product,
Elelyso/Uplyso, for the treatment of Gaucher disease in its
portfolio. Protalix has a worldwide commercialization partnership
(except Brazil and Israel) with
) for the product.
Oral GCD was observed to be safe and well-tolerated in all the
12 patients enrolled in the open label safety and pharmacokinetic
phase I study. The study examined the delivery of plant cell
expressed recombinant GCD following administration of Oral GCD in
No serious side effects were observed in the study. Enzyme
presence was also observed in patients' blood circulation and the
observed enzyme showed biological activity. Additionally
thrombocytopenia patients who had low platelet count exhibited a
significant improvement in platelet count.
The study has been extended to enroll additional Gaucher
patients with low platelet count. The study is expected to be
completed by year end.
We note that Protalix is making substantial efforts to develop
its pipeline and the company raised funds in Sep 2013 for the
Apart from PRX-112, the company has other interesting pipeline
candidates like PRX-102 (phase I/II - Fabry disease).
Furthermore, the company added three new compounds to its
pipeline, PRX-106 (immune mediated disorders), PRX-110 (cystic
fibrosis) and PRX-107 (emphysema) in Jun 2013.
Protalix carries a Zacks Rank #3 (Hold). Currently, companies
which look attractive include
AMAG Pharmaceuticals, Inc.
) with a Zacks Rank #1 (Strong Buy) and a Zacks Rank #2 (Buy),
ACTELION LTD (ALIOF): Get Free Report
AMAG PHARMA INC (AMAG): Free Stock Analysis
PFIZER INC (PFE): Free Stock Analysis Report
PROTALIX BIOTHR (PLX): Free Stock Analysis
To read this article on Zacks.com click here.